Advertisement

Indian Journal of Gastroenterology

, Volume 28, Issue 1, pp 28–30 | Cite as

Inflammatory bowel disease and coronary artery disease

  • Raja Shekhar R. Sappati BiyyaniEmail author
  • Nabil M. Fahmy
  • Elizabeth Baum
  • Karl M. Nelson
  • James F. King
Short Report

Abstract

Chronic inflammation with the presence of excess serum acute-phase proteins, cytokines and cell adhesion molecules is increasingly being implicated in atherosclerosis. The association between inflammatory bowel disease (IBD) and coronary artery disease (CAD) is unstudied. This is a preliminary, thesis-generating cross-sectional study aimed at evaluating the presence of traditional atherosclerotic risk factors in patients with IBD and CAD compared with the control population. The medical records of 42 consecutive IBD patients with CAD from 1999 to 2005 (27 men) were reviewed for the Framingham risk factors. The Framingham risk score (FRS) is calculated based on age, sex, hypertension, diabetes and hyperlipidemia. FRS of patients with IBD and CAD was compared with the FRS of 137 age- and sex-matched (102 men) consecutive patients with CAD (controls). When the Framingham risk score adjusted for group and gender with age as a covariate, the adjusted total FRS score was higher in patients with CAD alone (10.0 [3.75]) as compared to those with; IBD and CAD: (8.1 [3.47]; p = 0.001). FRS is lower in cases (patients with IBD and CAD) when compared with the controls (CAD alone).

Keywords

Framingham Heart Study Multivariate models Pathogenesis of atherosclerosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Zoccali C, Mallamaci F, Tripepi G. Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrol Dial Transplant 2004;19(suppl. 5):67–72.CrossRefGoogle Scholar
  2. 2.
    Maradit-Kremers H, Crowson CS, Nicola PJ. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis. Arthritis Rheumatism 2005;52:402–411.PubMedCrossRefGoogle Scholar
  3. 3.
    Shovman O, Gilburd B, Shoenfeld Y. The role of inflammatory cytokines in the pathogenesis of sytemic Lupus erythematosus-related atherosclerosis: a novel target for treatment. J Rheumatol 2006;33:445–447.PubMedGoogle Scholar
  4. 4.
    Deliargyris EN, Madianos PN, Kadoma W, et al. Periodontal disease in patients with acute myocardial infarction: prevalence and contribution to elevated C-reactive protein levels. Am Heart J 2004;147:1005–1009.PubMedCrossRefGoogle Scholar
  5. 5.
    Goggins MG, Goh J, O’Connell MA, et al. Soluble adhesion molecules in inflammatory bowel disease. Ir J Med Sci 2001;170:107–111.PubMedCrossRefGoogle Scholar
  6. 6.
    Wilson PWF. Assessing coronary heart disease risk with traditional and novel risk factors. Clin Cardiol 2004;27(suppl. III):III-7–III-11.Google Scholar
  7. 7.
    Ridker PM, Wilson PWF, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818–2825.PubMedCrossRefGoogle Scholar
  8. 8.
    Cucino C, Sonnenberg A. Cause of death in patients with inflammatory bowel disease. Inflamm Bowel Dis 2001;7:250–255.PubMedCrossRefGoogle Scholar
  9. 9.
    Ito H. Treatment of Crohn’s disease with anti-IL-6 receptor antibody. J Gastroenterol 2005;40(suppl. 16):32–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Kupcova V, Turecky L, Detkova Z, et al. Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohn’s disease. Physiol Res 2003;52:89–93.PubMedGoogle Scholar

Copyright information

© Indian Society of Gastroenterology 2009

Authors and Affiliations

  • Raja Shekhar R. Sappati Biyyani
    • 1
    • 2
    Email author
  • Nabil M. Fahmy
    • 4
  • Elizabeth Baum
    • 2
  • Karl M. Nelson
    • 3
  • James F. King
    • 4
  1. 1.Metro Health Medical CenterClevelandUSA
  2. 2.Canton Medical Education FoundationCantonUSA
  3. 3.Aultman HospitalCantonUSA
  4. 4.Gastroenterology & Hepatology Specialists Inc.CantonUSA

Personalised recommendations